PatientsVille.com Logo

EXPIRED PRODUCT ADMINISTERED and ALEVE

PatientsVille

EXPIRED PRODUCT ADMINISTERED Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for EXPIRED PRODUCT ADMINISTERED

EXPIRED PRODUCT ADMINISTERED treatment research studies

ALEVE clinical trials, surveys and public health registries


Find Drug Side Effect reports



ALEVE Side Effects

No Adverse Event (1413)
Nausea (722)
Dizziness (698)
Hypersensitivity (658)
Abdominal Pain Upper (643)
Pruritus (614)
Headache (536)
Dyspnoea (508)
Urticaria (487)
Arthralgia (429)
Abdominal Discomfort (394)
Blood Pressure Increased (383)
Vomiting (381)
Pain (349)
Swelling Face (339)
Dyspepsia (337)
Erythema (333)
Diarrhoea (315)
Back Pain (315)
Rash (305)
Oedema Peripheral (300)
Somnolence (299)
Insomnia (299)
Haematochezia (264)
Extra Dose Administered (263)
Fatigue (260)
Constipation (253)
Asthenia (237)
Incorrect Dose Administered (233)
Chest Pain (233)
Lip Swelling (222)
Feeling Abnormal (220)
Pain In Extremity (217)
Overdose (216)
Abdominal Pain (215)
Loss Of Consciousness (197)
Faeces Discoloured (181)
Throat Irritation (172)
Palpitations (160)
Eye Swelling (152)
Hyperhidrosis (141)
Arthritis (139)
Paraesthesia (138)
Contusion (133)
Feeling Hot (132)
Swollen Tongue (128)
Off Label Use (128)
Stomach Discomfort (125)
Rectal Haemorrhage (117)
Burning Sensation (116)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I took one Aleve at 3:30 PM and by 6:30 PM I had extreme abdominal pain lasting several hours and now the next day I still am uncomfortable. I will never take Aleve again!!

After taking aleve i was taken to the emergency room with a servere case of cellulitus on my hand and in my nose. The swelling itching and blisters were absolutely horrible and this pain lasted for days even after taking antibiotics and even having a

AFTER TAKING TWO ALEVE PILLS, I WOKE UP WITHIN TWO HOURS ITCHING IN THE PALM OF MY HANDS FIRST, THEN ALL OVER MY BODY. RASHES APPEARED, SWELLING AND HEART BEATING VERY FAST. MY LIPS LOOKED LIKE I HAD BOTOX . AL

Constant/terrible diahria and voimiting and nausea

Dry mouth/thirst

Extream skin itching

Got rash on legs and buttocks after using Aleve. Not painful...what should I do? Of course I stopped using it.

Have 2 herniated discs and shoulder tendonitis. Aleve relived shoulder pain better than cortisone shot. Am concerned about effects on creatinine though as mine is high normal.

How long should i take aleve?

I don't take anything but Aleve for mild joint pain. Nothing works as well for me--I only need to take 1 or 2 per day, but only on the days I have the joint pain. I always eat something first (a cracker) so it dosent't upset my stomach. I h

>:o Took my first dose today,it left me covered in a red itchy rash on neck,chest,back and sides within 10 minutes of consuming.This product is now sitting in the trash can. :(

<b>Describe Your Tazocin Experience Here:</b>after it was administered to my farther in hospital for the first time on day he was due to be released he had a cardiac arrest with multiple organ failure and subsequently died

'OCAS' means that the product is administered over a time period. For this reason it must be swallowed whole and not chewed.

....however, dalacine is very effective unto face. kaya ngaun patuloy na ang paggamit ko sa product na ito.. try niyo rin para masubukan niyo. sabi nga hindi mo malalaman ang tamis hangat hindi mo nasusubukan ang pa.it....jejejeje' &nb

1.2-methyl-2-butene is treated with the following reagents write the structural formula of the mian organic product in each case

10/10/11 Administered first Infliximab 14/10/11 had a venous sinus thrombosis.

2 weeks after second infusion for Hodgkin's Lymphome (& RA), I had an extreme respiratory problem (BOOP). I was hospitalized twice & had high steroid does IV along with IV antiobiotics administered. After 1 year of decreasing steroi

68 yo woman was administered erythromycin. Co-administered regular acidophilus to prevent diarrhea. After six days of effective dosage, # experienced severe abdominal pain/cramps and diarrhea w/bleeding. Administered electrolytes (potassium, s

According to unspsc classification ,in which commodity this product fall?

Aclasta inj was administered on me on 01st March 2012. Since then I am feeling giddy and have lost my vision. What is your responsibility about this?

EXPIRED PRODUCT ADMINISTERED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
Condition: Precancerous Condition
Interventions: Drug: naproxen;   Other: placebo;   Other: laboratory biomarker analysis
Outcome Measures: Change in PGE2 concentration levels in normal colorectal mucosa;   Minimal biologically effective dose of naproxen defined by modulation of PGE2 levels;   Response defined as >= 30% reduction in PGE2 levels;   Incidence of toxicity graded according to National Cancer Institute Common Criteria for Adverse Events (NCI CTCAE) version 4.0;   Naproxen concentrations in plasma samples;   Naproxen concentrations in normal colorectal mucosa;   PGE-M levels in urine samples;   Change in number of polyps observed in the rectosigmoid area;   Changes in the microRNA profile of the normal colorectal mucosa;   Changes in gene expression mRNA profiles of the normal colorectal mucosa;   Changes in the mutational rate of the normal colorectal mucosa
2 Unknown  Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee
Condition: Osteoarthritis, Knee
Interventions: Drug: Naproxen;   Drug: Placebo
Outcome Measures: Efficacy of naproxen vs. placebo;   Safety
3 Not yet recruiting Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
Conditions: Migraine;   Headache
Interventions: Drug: naratriptan + naproxen;   Drug: naratriptan;   Drug: naproxen
Outcome Measures: Headache relief 2 hours after dosing, without use of rescue medication;   Headache relief 4 hours after dosing, without use of rescue medication;   Maintenance of pain relief between 2 and 24 hours after dosing, without use of rescue medication;   Pain-free response 2 and 4 hours after dosing, without use of rescue medication;   Maintenance of pain-free response between 2 and 24 hours, without use of rescue medication;   Freedom from nausea, vomiting, photophobia and phonophobia 2 and 4 hours after dosing;   Maintenance of freedom from nausea, vomiting, photophobia and phonophobia between 2 and 24 hours after dosing, without use of rescue medication;   Recurrence of pain between 2 and 24 hours after dosing, without use of rescue medication;   Proportion of subjects who used rescue medication between 2 and 24 hours after dosing, at least once;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
4 Unknown  Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
Conditions: Migraine;   Headache
Interventions: Drug: Fixed-dose combination of naratriptan + naproxen;   Drug: Naratriptan;   Drug: Naproxen
Outcome Measures: Headache relief 2 hours after dosing, without use of rescue medication.;   Headache relief 4 hours after dosing, without use of rescue medication;   Sustained headache relief over 24 hours, without use of rescue medication;   Pain-free response 2 and 4 hours after dosing, without use of rescue medication;   Sustained pain-free response over 24 hours, without use of rescue medication;   Freedom from photophobia, phonophobia and nausea 2 and 4 hours after dosing, without use of rescue medication;   Sustained freedom from photophobia, phonophobia and nausea from 2 through 24 hours after dosing, without use of rescue medication;   Proportion of subjects who used rescue medication between 2 and 24 hours after dosing, at least once;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
5 Recruiting Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients
Conditions: Arthritis;   Cardiovascular Diseases;   Cerebrovascular Disorders
Interventions: Drug: Celecoxib(drug);   Drug: Naproxen(drug)
Outcome Measures: Recurrent ulcer bleeding within 78 weeks according to pre-specified criteria;   Cardiovascular events
6 Not yet recruiting Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects
Condition: Acute Pain
Interventions: Drug: Naproxen;   Drug: Sinemet;   Drug: Placebo
Outcome Measure: VAS pain scale
7 Not yet recruiting Effect of L-dopa In Subacute Back Pain Population
Condition: Sub-acute Back Pain
Interventions: Drug: Naproxen;   Drug: Carbidopa/Levodopa;   Drug: Placebo
Outcome Measure: VAS pain scale
8 Recruiting Efficacy of Sumatriptan With Naprosyn in Migraine With Aura
Condition: Migraine With Aura
Interventions: Drug: sumatriptan with naprosyn;   Drug: placebo
Outcome Measures: Primary outcome measure will be comparative percentage of patients pain free at 2 and 4 hours from initiating treatment with placebo vs treatment with Treximet (sumatriptan with naprosyn).;   Secondary outcomes will be percentage of patients with pain relief at 2 and 4 hours.
9 Recruiting NOLAN: Naproxen or Loratadine and Neulasta
Condition: Bone Pain in Stage I - III Breast Cancer
Interventions: Drug: Naproxen;   Drug: Loratadine
Outcome Measures: Bone pain (all grade) in cycle 1;   Bone pain (all grade) by cycle (2-4) and across cycles;   Severe (grade 3/4) bone pain by cycle and across cycles;   Subject reported bone pain;   Maximum Subject Reported bone pain;   Area under the Curve for subject-reported bone pain;   Adverse Event and Serious Adverse Events;   Severity of Adverse Events
10 Unknown  Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial
Condition: Pain, Postoperative
Interventions: Drug: naproxen;   Drug: placebo
Outcome Measures: cumulative opiate dose administered, as recorded on the computerized medication administration record (CMAR);   patient reported pain scores;   side effects of study medication and opiate analgesia
11 Recruiting The Effect of Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection
Conditions: Pleural Effusion;   Pleural Effusion Malignant
Interventions: Drug: Naproxen;   Drug: Placebo
Outcome Measures: Change in volume of pleural effusion collected;   Hospital length of stay; compared between intervention and control arms;   Gastrointestinal complications;   General re-admission rates;   Total number of days chest tubes remain in-situ
12 Recruiting Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
Condition: Arthritis, Rheumatoid
Interventions: Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Outcome Measures: The first occurrence of cardiovascular death (including hemorrhagic death), non-fatal myocardial infarction, or non-fatal stroke (APTC composite endpoint).;   The occurrence of Clinical Significant Gastrointestinal Events (CSGIEs);   Patient's Assessment of Arthritis Pain (VAS);   The first occurrence of a MACE defined as the composite of cardiovascular death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA
13 Not yet recruiting Colchicine Or Naproxen Treatment for ACute gouT
Condition: Gout
Interventions: Drug: Low-dose colchicine;   Drug: Naproxen
Outcome Measure: Change in pain intensity
14 Recruiting A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
Condition: Juvenile Idiopathic Arthritis (JIA)
Interventions: Drug: VIMOVO 250/20;   Drug: VIMOVO 375/20;   Drug: VIMOVO 500/20
Outcome Measures: Incidence of severity of AEs and SAEs.;   Change in serum iron/total iron binding capacity (serum iron/TIBC), Vitamin B12, and magnesium.;   Change from baseline in vital signs, physical examination results and clinical laboratory tests.;   Pharmacokinetic (PK) in terms of characteristics of VIMOVO (naproxen / esomeprazole).
15 Not yet recruiting Placebo In Chronic Pain
Condition: Chronic Back Pain
Interventions: Drug: Naproxen;   Drug: Placebo;   Drug: Omeprazole
Outcome Measure: VAS pain scale
16 Recruiting A Randomized Study of Three Medication Regimens for Acute Low Back Pain
Condition: Acute Low Back Pain
Interventions: Drug: Naproxen;   Drug: Cyclobenzaprine;   Drug: Oxycodone/ acetaminophen
Outcome Measure: Roland Morris low back pain functional disability scale
17 Recruiting Low Level Laser Therapy Versus Pharmacotherapy in in Improving Masticatory Muscle Pain
Condition: TMD
Interventions: Radiation: low level laser therapy;   Drug: Naproxen
Outcome Measure: reduction of paim measured by VAS
18 Recruiting Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment
Condition: Back Pain
Interventions: Drug: Ketorolac Tromethamine;   Drug: Naproxen
Outcome Measures: Efficacy of treatment in back pain relief based on Visual Analog Scale (VAS).;   Safety will be evaluated by the adverse events occurrences
19 Not yet recruiting Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment
Condition: Back Pain
Interventions: Drug: Ketorolac Tromethamine;   Drug: Naproxen
Outcome Measures: Efficacy of treatment in back pain relief based on Visual Analogic Score (VAS).;   Safety will be evaluated by the adverse events occurrences
20 Unknown  Ictal and Interictal Inflammatory Markers in Migraine
Condition: Migraine
Interventions: Drug: sumatriptan/naproxen sodium;   Drug: Placebo
Outcome Measure: Blood levels of proteins will be evaluated at baseline when subjects are pain-free and then repeated during an acute attack, both prior to drug administration and then at 30 minutes, 1 hour and 2 hours after acute treatment.